Navigation Links
Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
Date:2/10/2009

SCOTTSDALE, Ariz., Feb. 10 /PRNewswire/ -- Recent clinical data show that Restylane(R) lasted 18 months in 97% of patients with one repeat injection. Restylane(R) is the only HA filler with an 18-month FDA-approved duration claim.

These data were generated in a controlled, randomized, evaluator-blinded study that assessed the safety and effectiveness of two different retreatment schedules, 4.5 months or 9 months, after initial treatment of nasolabial folds (NLF). Patients were evaluated using the Wrinkle Severity Rating Scale (WSRS), a five-point scale to measure visual severity of wrinkles where five is the most severe rating (extreme). 92% of patients were naive to dermal fillers so had no residual effects from earlier treatment.

Key findings from the study include:

  • At 18 months, 97% of patients continued to show improvement in NLF correction with one repeat injection
  • Correction with Restylane(R) lasted for 18 months, regardless of retreatment schedule
  • At 18 months, patients still had a 1.7 grade improvement in WSRS over baseline
  • Adverse events were primarily swelling (24%) and bruising (19%); none were serious.

For more information, please contact Ilisa Wirgin or Elyse Koenig of LaForce + Stevens at 212.242.9353 x 140/167.

Restylane(R) is available only through a licensed practitioner. Complete product and safety information is available at www.RestylaneUSA.com.

To order Restylane please visit our Website at www.RestylaneUSA.com or call 877-520-0500

Safety information

Restylane(R) is indicated for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. The most commonly observed side effects are swelling, redness, pain, bruising, and tenderness at the injection site, which typically resolve in less than seven days. Avoid exposure of the treated area to excessive sun and UV lamp exposure and extreme cold weather until any initial swelling and redness have resolved. Safety has not been established for use during pregnancy, when breastfeeding, or in patients under 18 years.

Restylane is a trademark of HA North American Sales AB.


'/>"/>
SOURCE Medicis Aesthetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... Endo International plc (NASDAQ: ENDP ) will ... Members of its senior management team will host a conference call ... ET. The dial-in number to access the call ... and the passcode is 45397076. Please dial in 10 minutes prior ... A replay of the call will be available from August ...
(Date:7/12/2017)... 2017 CarpalAID is a revolutionary new product that relieves ... Carpal tunnel syndrome affects more than 8 million people a ... of men. The common methods of treating CTS are painful surgery, ... braces or gloves. ... CarpalAID is a clear patch worn on the palm ...
(Date:7/11/2017)... LINCOLNSHIRE, Ill. , July 11, 2017 /PRNewswire/ ... hematology and urinalysis diagnostic testing equipment as well ... latest innovation: a way to make quality assurance ... control processes. "Sysmex is well known for the ... SM Quality Monitor elevates quality assurance processes ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... BioPlus ... released an updated version of the HCV Treatment Path app (version 4.4.0) to ... C virus (HCV) infection. All of the latest HCV medications are included in ...
(Date:7/25/2017)... Deerfield Beach, Florida (PRWEB) , ... July 25, ... ... newest employee, Jennifer Haller, to the sales department joining as Regional Account Manager ... maintain relationships with contracted customers in the liquidation of their obsolete medical assets. ...
(Date:7/25/2017)... Spring Arbor, Mich. (PRWEB) , ... July 25, ... ... director of special education programs at Spring Arbor University recently co-authored and published ... of Self-Determination in Adolescents with Neonatal Brachial Plexus Palsy. Both the article and ...
(Date:7/25/2017)... ... July 25, 2017 , ... USHEALTH Group, Inc. ... the prestigious CEO World Awards®. The coveted annual CEO World Awards program encompasses ... case studies, corporate social responsibility, and milestones from every major industry in the ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya ... Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
Breaking Medicine News(10 mins):